Brightgene Bio-Medical Technology Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Public
- Established
- 2001-10-26
- Employees
- 1.1K
- Market Cap
- -
- Website
- http://www.bright-gene.com
A Study of BGM0504 in Chinese Patients With Type 2 Diabetes
Phase 2
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: BGM0504 Administered SCDrug: Semaglutide Administered SCDrug: Placebo Administered SC
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
- Target Recruit Count
- 67
- Registration Number
- NCT06974825
- Locations
- 🇨🇳
The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
A Study of BGM0504 Evaluating Weight Loss in Overweight or Obese Chinese Subjects
- First Posted Date
- 2025-05-15
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06973681
- Locations
- 🇨🇳
The Third Xiangya Hospital of Central South University, Changsha, China
A Study of BGM0504 in Healthy Participants and Participants With Impaired Renal Function
Phase 1
Recruiting
- Conditions
- Type 2 Diabetes Mellitus (T2DM)Overweight or Obese
- Interventions
- First Posted Date
- 2025-04-16
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT06929156
- Locations
- 🇨🇳
The First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital, Shandong Province), Jinan City, Shandong, China
A Study of BGM0504 in Overweight or Obese Participants
Phase 1
Recruiting
- Conditions
- Overweight or Obese
- Interventions
- First Posted Date
- 2025-04-09
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT06920056
- Locations
- 🇨🇳
The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine (Yunnan Provincial Hospital of Traditional Chinese Medicine), Kunming, Yunnan, China
A Study of BGM0504 in Participants With Obesity
- First Posted Date
- 2025-04-04
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT06911203
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
A Study of BGM0504 in Participants with Type 2 Diabetes
Phase 3
Recruiting
- Conditions
- Type 2 Diabetes Mellitus (T2DM)
- First Posted Date
- 2024-12-04
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
- Target Recruit Count
- 537
- Registration Number
- NCT06716216
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise
Phase 3
Recruiting
- Conditions
- Type 2 Diabetes Mellitus (T2DM)
- First Posted Date
- 2024-12-04
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
- Target Recruit Count
- 207
- Registration Number
- NCT06716203
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult Subjects
Phase 1
Active, not recruiting
- Conditions
- Non-diabetic Overweight or Obese
- First Posted Date
- 2024-12-04
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT06714955
- Locations
- 🇺🇸
Pharmaron CPC, Inc, Baltimore, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath